- Home
- NHS vs DSGN Comparison
NHS vs DSGN Comparison
Compare NHS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- DSGN
- Stock Information
- Founded
- NHS 2003
- DSGN 2017
- Country
- NHS United States
- DSGN United States
- Employees
- NHS N/A
- DSGN N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- DSGN Health Care
- Exchange
- NHS Nasdaq
- DSGN Nasdaq
- Market Cap
- NHS 221.6M
- DSGN 208.9M
- IPO Year
- NHS N/A
- DSGN 2021
- Fundamental
- Price
- NHS $7.49
- DSGN $3.82
- Analyst Decision
- NHS
- DSGN Hold
- Analyst Count
- NHS 0
- DSGN 1
- Target Price
- NHS N/A
- DSGN $4.00
- AVG Volume (30 Days)
- NHS 111.8K
- DSGN 83.6K
- Earning Date
- NHS 01-01-0001
- DSGN 08-04-2025
- Dividend Yield
- NHS 13.44%
- DSGN N/A
- EPS Growth
- NHS N/A
- DSGN N/A
- EPS
- NHS N/A
- DSGN N/A
- Revenue
- NHS N/A
- DSGN N/A
- Revenue This Year
- NHS N/A
- DSGN N/A
- Revenue Next Year
- NHS N/A
- DSGN N/A
- P/E Ratio
- NHS N/A
- DSGN N/A
- Revenue Growth
- NHS N/A
- DSGN N/A
- 52 Week Low
- NHS $6.95
- DSGN $2.60
- 52 Week High
- NHS $9.17
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- NHS 44.95
- DSGN 48.40
- Support Level
- NHS $7.37
- DSGN $3.65
- Resistance Level
- NHS $7.51
- DSGN $4.21
- Average True Range (ATR)
- NHS 0.07
- DSGN 0.23
- MACD
- NHS -0.02
- DSGN -0.00
- Stochastic Oscillator
- NHS 26.47
- DSGN 23.81
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.